ZA201205370B - Anaesthetic formulation - Google Patents
Anaesthetic formulationInfo
- Publication number
- ZA201205370B ZA201205370B ZA2012/05370A ZA201205370A ZA201205370B ZA 201205370 B ZA201205370 B ZA 201205370B ZA 2012/05370 A ZA2012/05370 A ZA 2012/05370A ZA 201205370 A ZA201205370 A ZA 201205370A ZA 201205370 B ZA201205370 B ZA 201205370B
- Authority
- ZA
- South Africa
- Prior art keywords
- anaesthetic formulation
- anaesthetic
- formulation
- Prior art date
Links
- 230000003444 anaesthetic effect Effects 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29724910P | 2010-01-21 | 2010-01-21 | |
| US38531810P | 2010-09-22 | 2010-09-22 | |
| PCT/AU2011/000050 WO2011088503A1 (en) | 2010-01-21 | 2011-01-19 | Anaesthetic formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201205370B true ZA201205370B (en) | 2013-09-25 |
Family
ID=44306295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2012/05370A ZA201205370B (en) | 2010-01-21 | 2012-07-18 | Anaesthetic formulation |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8697678B2 (enExample) |
| EP (1) | EP2525798B1 (enExample) |
| JP (1) | JP5930311B2 (enExample) |
| KR (1) | KR101747476B1 (enExample) |
| CN (1) | CN102802635B (enExample) |
| AU (1) | AU2011207103B2 (enExample) |
| BR (1) | BR112012017800B1 (enExample) |
| CA (1) | CA2786762C (enExample) |
| CL (1) | CL2012002032A1 (enExample) |
| CY (1) | CY1119947T1 (enExample) |
| DK (1) | DK2525798T3 (enExample) |
| ES (1) | ES2646829T3 (enExample) |
| GB (2) | GB2491491B (enExample) |
| HR (1) | HRP20171699T1 (enExample) |
| HU (1) | HUE035441T2 (enExample) |
| LT (1) | LT2525798T (enExample) |
| NO (1) | NO2525798T3 (enExample) |
| NZ (1) | NZ601255A (enExample) |
| PL (1) | PL2525798T3 (enExample) |
| PT (1) | PT2525798T (enExample) |
| RS (1) | RS56576B1 (enExample) |
| RU (1) | RU2574022C2 (enExample) |
| SG (1) | SG181997A1 (enExample) |
| SI (1) | SI2525798T1 (enExample) |
| SM (1) | SMT201700518T1 (enExample) |
| WO (1) | WO2011088503A1 (enExample) |
| ZA (1) | ZA201205370B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2812250T3 (es) | 2005-11-28 | 2021-03-16 | Marinus Pharmaceuticals Inc | Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| BR112014012985B1 (pt) * | 2011-11-29 | 2020-05-12 | Jurox Pty Ltd | Composição farmacêutica injetável, seu método de produção e uso, bem como método de conservação de uma composição farmacêutica injetável e uso de pelo menos um co-solvente e pelo menos um conservante |
| SMT202000008T1 (it) * | 2012-01-23 | 2020-03-13 | Sage Therapeutics Inc | Formulazione di steroide neuroattivo comprendente un complesso di allopregnanolone e solfobutil eter beta-ciclodestrina |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| PL2887944T3 (pl) * | 2012-08-21 | 2022-02-21 | Sage Therapeutics, Inc. | Allopregnanolon do leczenia lekoopornego stanu padaczkowego |
| US9757391B2 (en) | 2012-11-09 | 2017-09-12 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| ES2973320T3 (es) | 2012-11-30 | 2024-06-19 | Univ California | Alopregnanolona para tratar, reducir o mitigar los síntomas de la depresión posparto |
| WO2015134670A1 (en) * | 2014-03-05 | 2015-09-11 | Mingbao Zhang | Deuterated ganaxolone derivatives |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CA3254865A1 (en) * | 2015-02-06 | 2025-05-28 | Marinus Pharmaceuticals, Inc. | Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders |
| AR105044A1 (es) * | 2015-06-18 | 2017-08-30 | Sage Therapeutics Inc | Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente |
| US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
| AU2016338672A1 (en) * | 2015-10-16 | 2018-04-12 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| RU2766155C2 (ru) | 2016-03-08 | 2022-02-08 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, их композиции и применения |
| EP4233861A3 (en) | 2016-08-11 | 2023-10-11 | Ovid Therapeutics, Inc. | Compositions for treatment of essential tremor |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| CN111971238B (zh) | 2018-04-16 | 2022-02-18 | 川崎重工业株式会社 | 带式输送机 |
| SG11202012271VA (en) | 2018-07-03 | 2021-01-28 | Drawbridge Pharmaceuticals Pty Ltd | Neuroactive steroids and methods of preparation |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| AU2019396217A1 (en) * | 2018-12-10 | 2021-07-08 | Halo Science LLC | Stable formulations of anesthetics and associated dosage forms |
| CN114728012A (zh) | 2019-08-05 | 2022-07-08 | 马瑞纳斯制药公司 | 用于治疗癫痫持续状态的加奈索酮 |
| CN114828889B (zh) | 2019-12-06 | 2025-02-14 | 马瑞纳斯制药公司 | 用于治疗结节性硬化症的加奈索酮 |
| US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
| US12186327B2 (en) | 2022-08-29 | 2025-01-07 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0399716B1 (en) * | 1989-05-24 | 1994-01-26 | Innovet, Inc. | Hypoallergenic steroidal anesthetic/hypnotic compositions |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| WO1993017711A1 (en) | 1992-03-11 | 1993-09-16 | Australian Commercial Research & Development Limited | New cyclodextrins and new formulated drugs |
| US5472954A (en) * | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| JP4227675B2 (ja) * | 1996-10-25 | 2009-02-18 | 康武 日地 | 神経毒軽減麻酔剤 |
| AUPQ633900A0 (en) * | 2000-03-20 | 2000-04-15 | Jurox Pty Ltd | Anaesthetic composition |
| RU2288921C2 (ru) * | 2000-12-19 | 2006-12-10 | Калифорниа Инститьют оф Текнолоджи | Композиции, содержащие комплексы включения |
| US7034013B2 (en) | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| JP4334229B2 (ja) * | 2001-03-20 | 2009-09-30 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤 |
| IL152575A (en) | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | A skin-to-skin transmission system of water-insoluble drugs |
| ES2812250T3 (es) * | 2005-11-28 | 2021-03-16 | Marinus Pharmaceuticals Inc | Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas |
-
2011
- 2011-01-19 US US13/574,201 patent/US8697678B2/en active Active
- 2011-01-19 NZ NZ601255A patent/NZ601255A/xx not_active IP Right Cessation
- 2011-01-19 SG SG2012050159A patent/SG181997A1/en unknown
- 2011-01-19 EP EP11734245.1A patent/EP2525798B1/en active Active
- 2011-01-19 HR HRP20171699TT patent/HRP20171699T1/hr unknown
- 2011-01-19 HU HUE11734245A patent/HUE035441T2/en unknown
- 2011-01-19 KR KR1020127021761A patent/KR101747476B1/ko active Active
- 2011-01-19 ES ES11734245.1T patent/ES2646829T3/es active Active
- 2011-01-19 WO PCT/AU2011/000050 patent/WO2011088503A1/en not_active Ceased
- 2011-01-19 SI SI201131342T patent/SI2525798T1/en unknown
- 2011-01-19 DK DK11734245.1T patent/DK2525798T3/da active
- 2011-01-19 LT LTEP11734245.1T patent/LT2525798T/lt unknown
- 2011-01-19 CA CA2786762A patent/CA2786762C/en active Active
- 2011-01-19 GB GB1210657.1A patent/GB2491491B/en active Active
- 2011-01-19 RS RS20171135A patent/RS56576B1/sr unknown
- 2011-01-19 SM SM20170518T patent/SMT201700518T1/it unknown
- 2011-01-19 GB GB1201842.0A patent/GB2484244B/en active Active
- 2011-01-19 NO NO11734245A patent/NO2525798T3/no unknown
- 2011-01-19 BR BR112012017800-8A patent/BR112012017800B1/pt not_active IP Right Cessation
- 2011-01-19 RU RU2012134321/15A patent/RU2574022C2/ru active
- 2011-01-19 CN CN201180013975.2A patent/CN102802635B/zh not_active Expired - Fee Related
- 2011-01-19 PL PL11734245T patent/PL2525798T3/pl unknown
- 2011-01-19 JP JP2012549208A patent/JP5930311B2/ja active Active
- 2011-01-19 PT PT117342451T patent/PT2525798T/pt unknown
- 2011-01-19 AU AU2011207103A patent/AU2011207103B2/en active Active
-
2012
- 2012-07-18 ZA ZA2012/05370A patent/ZA201205370B/en unknown
- 2012-07-20 CL CL2012002032A patent/CL2012002032A1/es unknown
-
2013
- 2013-11-01 US US14/069,751 patent/US8975245B2/en active Active
-
2017
- 2017-11-07 CY CY20171101164T patent/CY1119947T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2491491B (en) | Anaesthetic formulation | |
| GB201010193D0 (en) | Medicinal use | |
| PL2865271T3 (pl) | Ulepszony preparat | |
| IL222637A0 (en) | Alcohol-resistant formulations | |
| ZA201206589B (en) | Incotine containing formulation | |
| PT2642980T (pt) | Formulação pediátrica | |
| ZA201300194B (en) | Formulations | |
| GB201110193D0 (en) | Formulations | |
| GB201013513D0 (en) | Formulations | |
| GB201012721D0 (en) | Headgear-mountable respirator | |
| GB201011138D0 (en) | Vaporiser | |
| GB201006326D0 (en) | Formulation | |
| ZA201300196B (en) | Formulations | |
| HK1169031B (en) | Anaesthetic formulation | |
| GB201002000D0 (en) | Formulation | |
| GB201001978D0 (en) | Formulation | |
| GB201005992D0 (en) | Formulation | |
| PL390421A1 (pl) | Preparat weterynaryjny | |
| PL393180A1 (pl) | Preparat weterynaryjny | |
| GB201010494D0 (en) | Formulations | |
| GB201012589D0 (en) | Formulations | |
| GB201018645D0 (en) | Formulations | |
| GB201007702D0 (en) | Formulations | |
| GB201008470D0 (en) | Formulations | |
| GB201007959D0 (en) | Formulations |